 This study will occur in two parts. Part 1 of the study will enroll ten 10 patients in the BPM31510 monotherapy arm and enroll ten 10 patients in the BPM31510 plus gemcitabine combination therapy arm. If at least one of ten patients treated in either arm experiences a Complete Response CR or Partial Response PR, based on RECIST 1.1 criteria, after 2 cycles of treatment, then Part 2 of the study will enroll an additional 15 patients for a total of 25 patients in the armss showing response. In the absence of at least one CR or PR, if at least 3 patients experience stable disease in either or both of the treatment arms the Sponsor can choose to enroll the additional 15 patients into the applicable treatment arms into the expansion stage. 